Skip to Main Content

Paper Details

Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Am J Hematol
18
2022
Author NameAffiliation
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Michael W DeiningerUniversity of Utah Huntsman Cancer Institute
Jorge CortesGeorgia Cancer Center
Daniel J DeAngeloDana-Farber Cancer Institute
John F DiPersioWashington University School of Medicine
Neil P ShahUniversity of California San Francisco
Hagop KantarjianComprehensive Cancer Center, University of Michigan ann arbor
  • 1 - 7

Datasets

Release 1.2